Ionis Pharma's Phase 3 OASIS-HAE Study Of Donidalorsen In Hereditary Angioedema Meets Main Goal

(RTTNews) - Ionis Pharmaceuticals, Inc. (IONS) Monday said Phase 3 OASIS-HAE study of donidalorsen in people with hereditary angioedema (HAE) met ...

Related Keywords

,European Medicines Agency ,Ionis Pharmaceuticals Inc ,Drug Administration ,New Drug Application ,Marketing Authorization Application ,European Medicines ,